Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line tr... by Billy Amzal, Shuai Fu, Jie Meng, Johanna Lister, Helene Karcher

Get full text